Earnings Call · Q1 FY2026·2026-05-11

Q4 25EPS -23.31%·Rev n/aQ3 25EPS +11.94%·Rev n/aQ2 25EPS +1.85%·Rev n/aQ1 25EPS -65.63%·Rev n/a⚠ consensus missing

LENZ Therapeutics, Inc. LENZ

Daniel Chevallard — Chief Financial Officer

Evert Schimmelpennink — President, CEO and Secretary

Shawn Olsson — Chief Commercial Officer

−20.8%1d on move date−20.7% vs SPY3d−27.0%5d−30.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LENZ calls or request research access.

More LENZ calls Browse calls Request research access